Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Wary Of Industry’s New Pre-Market Review Goal Proposals

This article was originally published in The Gray Sheet

Executive Summary

Recent device industry proposals for more aggressive pre-market review goals could result in fewer device clearances and approvals, FDA warns.

You may also be interested in...



FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability

FDA negotiators have warmed to the idea of total-time performance goals for the next round of medical device user fees, beginning in 2012, as long as FDA and industry share accountability for the time it takes to review new products.

FDA Embraces Total-Time Pre-Market Review Goals, With Shared Accountability

FDA negotiators have warmed to the idea of total-time performance goals for the next round of medical device user fees, beginning in 2012, as long as FDA and industry share accountability for the time it takes to review new products.

User Fee Talks On Schedule And Making Progress, Industry Says

Despite FDA warnings that time is running out for an agreement to be reached with industry on a user fee reauthorization plan, device industry leaders say the two sides have made “good progress” toward reaching a pact.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT030498

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel